AHA GUIDELINES Bundle (free trial)

Hypertrophic Cardiomyopathy 2024

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1521559

Contents of this Issue

Navigation

Page 36 of 43

37 Table 8. Antiarrhythmic Drug Therapy Options for Patients With HCM and AF Antiarrhythmic Drug Efficacy for AF Adverse Effects Toxicities Use in HCM Disopyramide Modest • Anticholinergic • HF • Prolonged QTc • TdP • Particularly with early onset AF • Generally used in conjunction with atrioventricular nodal blocking agents Flecainide and propafenone … Prolonged QRS • Proarrhythmia • Typical atrial flutter Not generally recommended in the absence of an ICD Sotalol Modest • Fatigue • Bradycardia • Prolonged QTc • TdP Reasonable Dofetilide Modest Headache • Prolonged QTc • TdP Reasonable Dronedarone Low HF Prolonged QTc ... Amiodarone Modest- high Bradycardia • Liver, lung, thyroid, skin, neurologic • Prolonged QTc Reasonable AF indicates atrial fibrillation; HCM, hypertrophic cardiomyopathy; HF, heart failure; ICD, implantable cardioverter-defibrillator; and TdP, torsades de pointes.

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Hypertrophic Cardiomyopathy 2024